Harmony Biosciences Holdings (HRMY) Total Non-Current Liabilities (2019 - 2026)

Harmony Biosciences Holdings has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $144.1 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $144.1 million, down 9.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $144.1 million (down 9.85% YoY), and the FY2025 annual result was $149.3 million, down 9.51% from the prior year.
• Total Non-Current Liabilities came in at $144.1 million for Q1 2026 at Harmony Biosciences Holdings, down from $149.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $193.0 million in Q1 2022 to a low of $144.1 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $177.3 million (2024), against an average of $173.3 million.
• Across the five-year window, Total Non-Current Liabilities grew 0.4% in 2022 and dropped 11.97% in 2025, its largest moves.
• Harmony Biosciences Holdings' Total Non-Current Liabilities stood at $192.1 million in 2022, then fell by 5.97% to $180.7 million in 2023, then slipped by 8.7% to $165.0 million in 2024, then declined by 9.51% to $149.3 million in 2025, then retreated by 3.45% to $144.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $144.1 million (Q1 2026), $149.3 million (Q4 2025), and $149.7 million (Q3 2025), per Business Quant data.